Unity Biotechnology rises on eye disorder drug trial data

Unity Biotechnology

27/09/2023 14:04

** Shares of drug developer Unity Biotechnology  UBX.O  rise
3.8% to $2.47 premarket
    ** Company says its combination treatment with Regeneron's
 REGN.O  aflibercept showed greater vision improvement in
patients with wet age-related macular degeneration (AMD) during
a mid-stage trial
    ** The drug, UBX1325, helped patients with prior anti-VEGF
treatment to maintain visual clarity through 24 weeks but showed
a decrease from baseline at week 48
    ** Wet AMD is an eye disorder that causes blurred vision or
a blind spot in the central vision
    ** Anti-VEGF treatment stops abnormal growth of new blood
vessels in the eye
    ** Up to last close, shares down 13.1% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))